Current and Emerging Biologic Therapies for Severe Asthma - PubMed
3 hours ago
- #severe-asthma
- #monoclonal-antibodies
- #biologic-therapies
- Severe asthma is a heterogeneous disorder with persistent symptoms and frequent exacerbations despite optimized therapy.
- Seven monoclonal antibodies are approved, targeting IgE, IL-5/IL-5 receptor α, IL-4 receptor α, and TSLP, reducing exacerbations and corticosteroid use.
- Key predictors of response include blood eosinophil counts and phenotype-specific biomarkers.
- Current biologics have limitations in treating type 2-low, neutrophilic, and mixed phenotypes, as well as airway remodeling.
- Emerging strategies target upstream alarmins, multi-cytokine pathways, and IgE-producing B cells for improved outcomes.
- Novel approaches include Fc-engineered anti-IgE antibodies and bispecific/trispecific agents for broader pathway blocking.
- Future directions focus on disease-modifying effects and biomarker-guided personalized therapy for severe asthma.